title: Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins.
authors: 1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Postgraduate School of Molecular Medicine, Warsaw, Poland.
authors: M
authors: M
authors: Dwojak
authors: 1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Postgraduate School of Molecular Medicine, Warsaw, Poland.
authors: M
authors: M
authors: Bobrowicz
authors: 1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland.
authors: J
authors: J
authors: Bil
authors: 1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Postgraduate School of Molecular Medicine, Warsaw, Poland.
authors: K
authors: K
authors: Bojarczuk
authors: Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
authors: B
authors: B
authors: Pyrzynska
authors: 1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Postgraduate School of Molecular Medicine, Warsaw, Poland.
authors: M
authors: M
authors: Siernicka
authors: Department of Haematology, Institute of Haematology and Transfusion Medicine, Warsaw, Poland.
authors: A
authors: A
authors: Malenda
authors: 1] Department of Haematology, Institute of Haematology and Transfusion Medicine, Warsaw, Poland [2] Department of Haematology and Transfusion Medicine, Centre of Postgraduate Medical Education, Warsaw, Poland.
authors: E
authors: E
authors: Lech-Maranda
authors: Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
authors: W
authors: W
authors: Tomczak
authors: Department of Experimental Haematooncology, Medical University of Lublin, Lublin, Poland.
authors: K
authors: K
authors: Giannopoulos
authors: 1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Institute of Physical Chemistry, Polish Academy of Sciences, Department 3, Warsaw, Poland.
authors: J
authors: J
authors: Golab
authors: Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
authors: M
authors: M
authors: Winiarska
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D003165:Complement System Proteins / Q000096:biosynthesis / Q000235:genetics; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage*; D000069283:Rituximab; D000077157:Sorafenib
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D010671:Phenylurea Compounds; D009536:Niacinamide; D000069283:Rituximab; D003165:Complement System Proteins; D000077157:Sorafenib; C527517:ofatumumab